Literature DB >> 3197753

Biliary excretion of phenprocoumon and metabolites.

J X de Vries1, R Raedsch, U Völker, I Walter-Sack, E Weber.   

Abstract

To evaluate phenprocoumon elimination its possible biliary excretion was evaluated in addition to the known pathway of renal elimination. Bile samples were obtained during diagnostic endoscopy in patients receiving chronic phenprocoumon therapy and were analyzed for phenprocoumon and its metabolites by HPLC and GC-MS. The following substances were detected, mainly in conjugated form: unchanged phenprocoumon and the metabolites 7-hydroxy-, 4'-hydroxy-, and 6-hydroxy-phenprocoumon. The data provide direct evidence of the biliary elimination of unchanged phenprocoumon and its metabolites in humans.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3197753     DOI： 10.1007/bf00561379

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  7 in total

1.  Effect of cholestyramine on the gastrointestinal absorption of phenprocoumon and acetylosalicylic acid in man.

Authors:  K J Hahn; W Eiden; M Schettle; M Hahn; E Walter; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1972-06       Impact factor: 2.953

2.  Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine.

Authors:  T Meinertz; H J Gilfrich; U Groth; H G Jonen; E Jähnchen
Journal:  Clin Pharmacol Ther       Date:  1977-06       Impact factor: 6.875

3.  Biotransformation of phenprocoumon in the rat.

Authors:  L R Pohl; R E Haddock; W F Trager
Journal:  J Med Chem       Date:  1975-05       Impact factor: 7.446

4.  Determination of the anticoagulant phenprocoumon in human plasma and urine by high-performance liquid chromatography.

Authors:  J X De Vries; J Harenberg; E Walter; R Zimmermann; M Simon
Journal:  J Chromatogr       Date:  1982-08-13

5.  Identification of phenprocoumon metabolites in human urine by high-performance liquid chromatography and gas chromatography-mass spectrometry.

Authors:  J X De Vries; M Simon; R Zimmermann; J Harenberg
Journal:  J Chromatogr       Date:  1985-03-22

6.  Phenprocoumon metabolites in human plasma; characterization by HPLC and GC-MS.

Authors:  J X de Vries; R Zimmermann; J Harenberg
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Metabolic fate of phenprocoumon in humans.

Authors:  S Toon; L D Heimark; W F Trager; R A O'Reilly
Journal:  J Pharm Sci       Date:  1985-10       Impact factor: 3.534
  7 in total
  4 in total

Review 1.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Self-medication for abdominal discomfort resulting in life-threatening consequences.

Authors:  T Schlenker; R Raedsch; J X DeVries; E Schmitz-Kummer; I Walter-Sack; E M Rothe; B Kommerell
Journal:  Clin Investig       Date:  1993-12

Review 3.  Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

Authors:  Simone Stehle; Julia Kirchheiner; Andreas Lazar; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

4.  Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model.

Authors:  Khaled Abduljalil; Simone Lazar; Michael Natanzon; Weidong Wu; Gregor Zadoyan; Benedict Steffens; Victoria Kohl; Klaus Mörike; Dorota Tomalik-Scharte; Julia Stingl; Matthias Schwab; Job Harenberg; Christoph Gleiter; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.